|
|
| Introduction The antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and warfarin, respectively). Reasons to Purchase
|
Related Markets
Cardiovascular Reports
- Cardiovascular Partnering Terms and Agreements
- International Stroke Conference 2012 - Post-Conference Review and Analysis
- 6th Asian Pacific Congress of Heart Failure (APCHF) - Post-Conference Review and Analysis
- Arrhythmias Global Clinical Trials Review, H1, 2012
- Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018
